ABSTRACT
ABCIXIMAB/REOPRO Antiplatelet agent – monoclonal Ab against platelet glycoprotein IIb/ IIIa receptor (involved in Pt aggregation). Use: Px of ischaemic complications of PCI and Px of MI in unstable angina unresponsive to conventional Rx awaiting PCINICE (see p. 240). CI: active internal bleeding, CVA w/in 2 years, intracranial neoplasm, aneurysm or AVM. Major surgery, intracranial/ intraspinal surgery or trauma w/in 2 months. Hypertensive retinopathy, vasculitis, ↓Pt, haemorrhagic diathesis, severe ↑BP. L (if severe)/R (if requiring haemodialysis)/B. Caution: drugs that ↑bleeding risk, L/R/P/E. SE: bleeding* /↓Pt*, N&V, ↓BP, ↓HR, pain (chest, back or pleuritic), headache, fever, oedema. Rarely, hypersensitivity, tamponade, ARDS. Monitor: FBC* (baseline plus 2-4 h, 12 h and 24 h after giving) and clotting (baseline at least). Dose: 250 microgram/kg iv over 1 min, then 0.125 microgram/kg/ min (max 10 microgram/min) ivi; see BNF/product literature for dose timing. NB: use iv non-pyrogenic, low protein binding filter. Needs concurrent heparin. Specialist use only: get senior advice or contact on-call cardiology.
